Wednesday, 3 December 2008

Letrozole (Femara): Mylan settled with innovator

Mylan pharma announced in a press release Here, that Mylan have settled with innovator Nowartis with respect to their pending patent litigation on Letrozole tablets pending at New Jersy District court since June, 2006. Mylan in a bid to market generic version of Novartis's Femara (Letrozole) tablets 2.5 mg, filed ANDA in 2006. Subsequently, innovator sued Mylan in New Jersy District court for the infringement of US4978672 (Expiry: June 3,2011): Which covers Alpha-heterocyclc substituted tolunitriles as product (including Letrozole)
Under the agreement, Mylan is provided a patent license that will enable the company to market Letrozole Tablets, 2.5 mg, prior to the expiration of '672 patent. Additional terms related to the settlement remain confidential, and the agreement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Accordingly, an early generic launch by Mylan is on the cards.

No comments:

web page statistics
web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker